NJ Bio, Inc. and Ajinomoto Bio‑Pharma Services Enter into Collaboration to Strengthen Support for Antibody-Drug Conjugate Development

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Ajinomoto-Bio-Pharma

More Like This

PR Newswire associated0

Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.

PR Newswire associated0

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

PR Newswire associated0

Ajinomoto Bio-Pharma Services and Gene Tools Announce Collaboration to Expand Access to PMO Therapeutics

PR Newswire associated0

Ajinomoto Bio-Pharma Services and Olon S.p.A. Form Strategic Partnership to Advance Large-Scale Peptide and Protein Manufacturing

NJ Bio, Inc. now offers translational research services after completing asset purchase and full integration of the services of L2P® Research Labs, enhancing the discovery-to-development pipeline

NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P® Services

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Leaders from SK pharmteco and LOTTE BIOLOGICS at the LOTTE BIOLOGICS booth at CPHI Frankfurt, Germany, following the signing of the strategic collaboration Letter of Intent on October 29, 2025. From left to right: Joon Chang, CBO, LOTTE BIOLOGICS; Jiwon Chun, CGO, LOTTE BIOLOGICS; Kern Chang, CTO, LOTTE BIOLOGICS; Yooyeol Shin, CSO, LOTTE BIOLOGICS; James Park, CEO, LOTTE BIOLOGICS; Joerg Ahlgrimm, CEO, SK pharmteco; Andy Fenny, CCO, SK pharmteco; Olivia Boyce, Global Head of Proposals, SK pharmteco; Shiuk Lee, CSO, SK pharmteco; Steve Barr, Head of Small Molecule, SK pharmteco.

SK pharmteco and LOTTE BIOLOGICS Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family